Author of

• 20167

  +

  P2.03 - Chemotherapy/Targeted Therapy (ID 704)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Chemotherapy/Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23326

    +

    P2.03-055 - Comparison of Afatinib Versus Erlotinib for Advanced Non-Small-Cell Lung Cancer Patients with Resistance to EGFR-TKI (ID 10463)

    09:30 - 09:30  |  Author(s): Y.H. Kim
    • Abstract

    Background:
    Afatinib, an irreversible ErbB-family blocker, has shown activity for patients with advanced non-small-cell lung cancer (NSCLC) after failure of gefitinib or/and erlotinib in LUX-LUNG1 trial; however, efficacy data of EGFR-TKI re-challenge with afatinib is insufficient.
    
    Method:
    We retrospectively reviewed medical record of the patients with advanced NSCLC harboring EGFR mutation whose disease progressed after the treatment with gefitinib or erlotinib and received EGFR-TKI re-challenge at Kyoto University Hospital between Apr 2008 and Mar 2017, and compared the efficacy of afatinib after the failure of gefitinib or erlotinib and erlotinib after the failure of gefitinib.
    
    Result:
    Sixty-two patients were identified, including 13 patients with afatinib and 49 patients with erlotinib. Patient characteristics, such as age, sex, ECOG-PS and smoking status, were not significantly different between the treatment groups. In the afatinib group, 8 patients had received erlotinib as their initial EGFR-TKI and 5 patients had received gefitinib. In the erlotinib group, all patients had received gefitinib as their initial EGFR-TKI. EGFR T790M mutation status was unknown in all patients when EGFR-TKI was re-administrated. Overall response rate (ORR) was 12.7% and disease control rate (DCR) was 54.5% in the entire population. ORR in the afatinib group and the erlotinib group were 7.7% and 14.3%, respectively (p=0.513), and DCR in the afatinib group and the erlotinib group were 61.5% and 52.4%, respectively (p=0.561). Median progression-free survival was 2.4 months in the entire population (95% confidence interval [CI], 1.8-3.3), and 3.9 months in the afatinib group and 2.3 months in the erlotinib group, respectively (hazard ratio [HR] = 0.698 (95% CI, 0.351-1.285), p=0.258).
    
    Conclusion:
    Re-challenge with EGFR-TKI demonstrated clinical benefit as previously reported. No significant difference was observed between the efficacy of afatinib after the failure of gefitinib or erlotinib and that of erlotinib after the failure of gefitinib.